Publish in this journal
Journal Information
Vol. 17. Issue 6.
Pages 364-365 (June - July 2021)
Share
Share
Download PDF
More article options
ePub
Visits
...
Vol. 17. Issue 6.
Pages 364-365 (June - July 2021)
Case Report
DOI: 10.1016/j.reuma.2020.04.014
Remission of Rheumatoid Arthritis and Primary Biliary Cholangitis After Treatment With Tocilizumab
Remisión de artritis reumatoide y colangitis biliar primaria tras tratamiento con tocilizumab
Visits
...
Soraia Azevedoa,
Corresponding author
, Joana Sousa-Nevesb, Joana Ramos Rodriguesa, Daniela Peixotoa, José Tavares-Costaa, Filipa Teixeiraa
a Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal
b Rheumatology Department, Hospital de Braga, Portugal
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract

Rheumatoid arthritis (RA) is characterized by synovitis of multiple joints which if untreated progresses to joint destruction. Primary biliary cholangitis (PBC) is an autoimmune and progressive disease of the liver of unknown origin. About 1.8–5.6% of individuals with PBC have RA and patients with RA are at higher risk of developing PBC compared to the general population.

We report a case of a 76-year-old man, with a history of PBC, and a recent RA diagnosis, in which tocilizumab therapy was effective in the control of RA and PBC, and a literature review was performed.

This case, along with only one case published in literature in which tocilizumab was used in the treatment of RA and PBC, suggests that tocilizumab may be effective and safe in the treatment of RA in patients with PBC. Inhibition of IL-6 may also be effective in PBC treatment.

Keywords:
Rheumatoid arthritis
Primary biliary cholangitis
Tocilizumab
IL-6
Resumen

La artritis reumatoide (AR) se caracteriza por sinovitis de múltiples articulaciones que, de no tratarse, deriva en destrucción articular. La colangitis biliar primaria (CBP) es una enfermedad hepática autoinmune y progresiva de origen desconocido. Cerca del 1,8-5,6% de los individuos con CBP padecen AR, y los pacientes con AR tienen mayor riesgo de desarrollar CBP, en comparación con la población general.

Reportamos el caso de un varón de 76 años con historia de CBP y diagnóstico reciente de AR, en el que la terapia con tocilizumab fue efectiva para el control de ambas situaciones y realizamos una revisión de la literatura sobre el caso.

Este caso junto con otro publicado en la literatura, en el que se utilizó tocilizumab para tratar CBP y AR, sugieren que este fármaco puede ser efectivo y seguro para el tratamiento de AR en pacientes con CBP. La inhibición de IL-6 puede resultar también eficaz en el tratamiento de la CBP.

Palabras clave:
Artritis reumatoide
Colangitis biliar primaria
Tocilizumab
IL-6

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?